Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Yamshchikov, G; Thompson, L; Ross, WG; Galavotti, H; Aquila, W; Deacon, D; Caldwell, J; Patterson, JW; Hunt, DF; Slingluff, CL
   Analysis of a natural immune response against tumor antigens in a melanomasurvivor: Lessons applicable to clinical trial evaluations
   CLINICAL CANCER RESEARCH
   
   G. Yamshchikov et al., "Analysis of a natural immune response against tumor antigens in a melanomasurvivor: Lessons applicable to clinical trial evaluations", CLIN CANC R, 7(3), 2001, pp. 909S-916S
2. Slingluff, CL; Yamshchikov, G; Neese, P; Galavotti, H; Eastham, S; Engelhard, VH; Kittlesen, D; Deacon, D; Hibbitts, S; Grosh, WW; Petroni, G; Cohen, R; Wiernasz, C; Patterson, JW; Conway, BP; Ross, WG
   Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes
   CLINICAL CANCER RESEARCH
   
   C.L. Slingluff et al., "Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes", CLIN CANC R, 7(10), 2001, pp. 3012-3024
3. Brinckerhoff, LH; Thompson, LW; Slingluff, CL
   Melanoma vaccines (vol 12, pg 163, 2000)
   CURRENT OPINION IN ONCOLOGY
   
   L.H. Brinckerhoff et al., "Melanoma vaccines (vol 12, pg 163, 2000)", CURR OPIN O, 13(5), 2001, pp. 413-413
4. Harlow, SP; Krag, DN; Ashikaga, T; Weaver, DL; Meijer, SJ; Loggie, BW; Tanabe, KK; Whitworth, P; Kuhn, J; Kusminsky, R; Carp, NZ; Gadd, M; Rawlings, M; Slingluff, CL
   Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study
   MELANOMA RESEARCH
   
   S.P. Harlow et al., "Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study", MELANOMA RE, 11(1), 2001, pp. 45-55
5. Kilbridge, KL; Weeks, JC; Sober, AJ; Haluska, FG; Slingluff, CL; Atkins, MB; Sock, DE; Kirkwood, JM; Nease, RF
   Patient preferences for adjuvant interferon alfa-2b treatment
   JOURNAL OF CLINICAL ONCOLOGY
   
   K.L. Kilbridge et al., "Patient preferences for adjuvant interferon alfa-2b treatment", J CL ONCOL, 19(3), 2001, pp. 812-823
6. Slingluff, CL; Colella, TA; Thompson, L; Graham, DD; Skipper, JCA; Caldwell, J; Brinckerhoff, L; Kittlesen, DJ; Deacon, DH; Oei, C; Harthun, NL; Huczko, EL; Hunt, DF; Darrow, TL; Engelhard, VH
   Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens
   CANCER IMMUNOLOGY IMMUNOTHERAPY
   
   C.L. Slingluff et al., "Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens", CANCER IMMU, 48(12), 2000, pp. 661-672
7. Slingluff, CL
   'Mastectomy'
   VIRGINIA QUARTERLY REVIEW
   
   C.L. Slingluff, "'Mastectomy'", VA Q REV, 76(4), 2000, pp. 662-663
8. Zarour, HM; Kirkwood, JM; Kierstead, LS; Herr, W; Brusic, V; Slingluff, CL; Sidney, J; Sette, A; Storkus, WJ
   Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitoperecognized by melanoma-reactive CD4(+) T cells
   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
   
   H.M. Zarour et al., "Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitoperecognized by melanoma-reactive CD4(+) T cells", P NAS US, 97(1), 2000, pp. 400-405
9. Yang, SX; Kittlesen, D; Slingluff, CL; Vervaert, CE; Seigler, HF; Darrow, TL
   Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and-A3
   JOURNAL OF IMMUNOLOGY
   
   S.X. Yang et al., "Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and-A3", J IMMUNOL, 164(8), 2000, pp. 4204-4211
10. English, JC; Middleton, C; Patterson, JW; Slingluff, CL
    Cancer of the male breast
    INTERNATIONAL JOURNAL OF DERMATOLOGY
    
    J.C. English et al., "Cancer of the male breast", INT J DERM, 39(12), 2000, pp. 881-886
11. Lippolis, JD; Denis-Mize, KS; Brinckerhoff, LH; Slingluff, CL; Galloway, DR; Engelhard, VH
    Pseudomonas exotoxin-mediated delivery of exogenous antigens to MHC class I and class II processing pathways
    CELLULAR IMMUNOLOGY
    
    J.D. Lippolis et al., "Pseudomonas exotoxin-mediated delivery of exogenous antigens to MHC class I and class II processing pathways", CELL IMMUN, 203(2), 2000, pp. 75-83
12. Moore, MM; Borossa, G; Imbrie, JZ; Fechner, RE; Harvey, JA; Slingluff, CL; Adams, RB; Hanks, JB
    Association of infiltrating lobular carcinoma with positive surgical margins after breast-conservation therapy
    ANNALS OF SURGERY
    
    M.M. Moore et al., "Association of infiltrating lobular carcinoma with positive surgical margins after breast-conservation therapy", ANN SURG, 231(6), 2000, pp. 877-881
13. Slingluff, CL
    Immunology of cancer
    SURGERY: BASIC SCIENCE AND CLINICAL EVIDENCE
    
    C.L. Slingluff, "Immunology of cancer", SURGERY: BASIC SCIENCE AND CLINICAL EVIDENCE, 2000, pp. 1641-1657
14. Slingluff, CL
    Targeting unique tumor antigens and modulating the cytokine environment may improve immunotherapy for tumors with immune escape mechanisms
    CANCER IMMUNOLOGY IMMUNOTHERAPY
    
    C.L. Slingluff, "Targeting unique tumor antigens and modulating the cytokine environment may improve immunotherapy for tumors with immune escape mechanisms", CANCER IMMU, 48(7), 1999, pp. 371-373
15. Kittlesen, DJ; Thompson, LW; Gulden, PH; Skipper, JCA; Colella, TA; Shabanowitz, J; Hunt, DF; Engelhard, VH; Slingluff, CL
    Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development (vol 160, pg 2099, 1998)
    JOURNAL OF IMMUNOLOGY
    
    D.J. Kittlesen et al., "Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: Implications for tumor vaccine development (vol 160, pg 2099, 1998)", J IMMUNOL, 162(5), 1999, pp. 3106-3106
16. Brinckerhoff, LH; Kalashnikov, VV; Thompson, LW; Yamshchikov, GV; Pierce, RA; Galavotti, HS; Engelhard, VH; Slingluff, CL
    Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: Implications for peptide vaccines
    INTERNATIONAL JOURNAL OF CANCER
    
    L.H. Brinckerhoff et al., "Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: Implications for peptide vaccines", INT J CANC, 83(3), 1999, pp. 326-334
17. Skipper, JCA; Gulden, PH; Hendrickson, RC; Harthun, N; Caldwell, JA; Shabanowitz, J; Engelhard, VH; Hunt, DF; Slingluff, CL
    Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifiesdominant naturally processed forms of CTL epitopes from MART-1 and gp100
    INTERNATIONAL JOURNAL OF CANCER
    
    J.C.A. Skipper et al., "Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifiesdominant naturally processed forms of CTL epitopes from MART-1 and gp100", INT J CANC, 82(5), 1999, pp. 669-677
18. HARTHUN NL; WEAVER AM; BRINCKERHOFF LH; DEACON DH; GONIAS SL; SLINGLUFF CL
    ACTIVATED ALPHA(2)-MACROGLOBULIN REVERSES THE IMMUNOSUPPRESSIVE ACTIVITY IN HUMAN BREAST-CANCER CELL-CONDITIONED MEDIUM BY SELECTIVELY NEUTRALIZING TRANSFORMING-GROWTH-FACTOR-BETA IN THE PRESENCE OF INTERLEUKIN-2
    Journal of immunotherapy
    
    N.L. Harthun et al., "ACTIVATED ALPHA(2)-MACROGLOBULIN REVERSES THE IMMUNOSUPPRESSIVE ACTIVITY IN HUMAN BREAST-CANCER CELL-CONDITIONED MEDIUM BY SELECTIVELY NEUTRALIZING TRANSFORMING-GROWTH-FACTOR-BETA IN THE PRESENCE OF INTERLEUKIN-2", Journal of immunotherapy, 21(2), 1998, pp. 85-94
19. WANG TS; LOWE L; SMITH JW; FRANCIS IR; SONDAK VK; DWORZANIAN L; FINKELSTEIN S; SLINGLUFF CL; JOHNSON TM
    COMPLETE SPONTANEOUS REGRESSION OF PULMONARY METASTATIC MELANOMA
    Dermatologic surgery
    
    T.S. Wang et al., "COMPLETE SPONTANEOUS REGRESSION OF PULMONARY METASTATIC MELANOMA", Dermatologic surgery, 24(8), 1998, pp. 915-919
20. COLELLA TA; KITTLESEN DJ; LUCKEY CJ; THOMPSON LW; SLINGLUFF CL; ENGELHARD VH
    THE PRESENTATION OF PEPTIDE ANTIGENS DERIVED FROM MELANOCYTE-DIFFERENTIATION PROTEINS BY CULTURED MELANOCYTES - IMPLICATIONS FOR TUMOR-IMMUNOTHERAPY
    The FASEB journal
    
    T.A. Colella et al., "THE PRESENTATION OF PEPTIDE ANTIGENS DERIVED FROM MELANOCYTE-DIFFERENTIATION PROTEINS BY CULTURED MELANOCYTES - IMPLICATIONS FOR TUMOR-IMMUNOTHERAPY", The FASEB journal, 12(4), 1998, pp. 1685-1685
21. SETTLAGE RE; HENDRICKSON RC; DEACON D; CALDWELL JA; HUNT DF; SLINGLUFF CL
    A PEPTIDE FROM P68 IS AN EPITOPE FOR MELANOMA REACTIVE CYTOTOXIC T-LYMPHOCYTES
    The FASEB journal
    
    R.E. Settlage et al., "A PEPTIDE FROM P68 IS AN EPITOPE FOR MELANOMA REACTIVE CYTOTOXIC T-LYMPHOCYTES", The FASEB journal, 12(4), 1998, pp. 2766-2766
22. BRINCKERHOFF LH; GULDEN PH; HUNT DF; SLINGLUFF CL
    AT LEAST 3 HLA-A-ASTERISK-0201 ASSOCIATED MELANOMA PEPTIDE EPITOPES ARE SHED FROM GP100 POSITIVE CULTURED MELANOMA CELL-LINES
    The FASEB journal
    
    L.H. Brinckerhoff et al., "AT LEAST 3 HLA-A-ASTERISK-0201 ASSOCIATED MELANOMA PEPTIDE EPITOPES ARE SHED FROM GP100 POSITIVE CULTURED MELANOMA CELL-LINES", The FASEB journal, 12(4), 1998, pp. 2767-2767
23. BRINCKERHOFF LH; DEACON D; KITTLESEN DJ; SLINGLUFF CL
    CRYOPRESERVATION OF HUMAN MONOCYTE-DERIVED CELLS FOR USE IN MELANOMA VACCINES
    Journal of leukocyte biology
    
    L.H. Brinckerhoff et al., "CRYOPRESERVATION OF HUMAN MONOCYTE-DERIVED CELLS FOR USE IN MELANOMA VACCINES", Journal of leukocyte biology, 1998, pp. 25-25
24. KITTLESEN DJ; THOMPSON LW; GULDEN PH; SKIPPER JCA; COLELLA TA; SHABANOWITZ JA; HUNT DF; ENGELHARD VH; SLINGLUFF CL
    HUMAN-MELANOMA PATIENTS RECOGNIZE AN HLA-A1-RESTRICTED CTL EPITOPE FROM TYROSINASE CONTAINING 2 CYSTEINE RESIDUES - IMPLICATIONS FOR TUMOR VACCINE DEVELOPMENT
    The Journal of immunology
    
    D.J. Kittlesen et al., "HUMAN-MELANOMA PATIENTS RECOGNIZE AN HLA-A1-RESTRICTED CTL EPITOPE FROM TYROSINASE CONTAINING 2 CYSTEINE RESIDUES - IMPLICATIONS FOR TUMOR VACCINE DEVELOPMENT", The Journal of immunology, 160(5), 1998, pp. 2099-2106
25. TUTING T; WILSON CC; MARTIN DM; KASAMON YL; ROWLES J; MA DI; SLINGLUFF CL; WAGNER SN; VANDERBRUGGEN P; BAAR J; LOTZE MT; STORKUS WJ
    AUTOLOGOUS HUMAN MONOCYTE-DERIVED DENDRITIC CELLS GENETICALLY-MODIFIED TO EXPRESS MELANOMA ANTIGENS ELICIT PRIMARY CYTOTOXIC T-CELL RESPONSES IN-VITRO - ENHANCEMENT BY COTRANSFECTION OF GENES ENCODING THE TH1-BIASING CYTOKINES IL-12 AND IFN-ALPHA
    The Journal of immunology
    
    T. Tuting et al., "AUTOLOGOUS HUMAN MONOCYTE-DERIVED DENDRITIC CELLS GENETICALLY-MODIFIED TO EXPRESS MELANOMA ANTIGENS ELICIT PRIMARY CYTOTOXIC T-CELL RESPONSES IN-VITRO - ENHANCEMENT BY COTRANSFECTION OF GENES ENCODING THE TH1-BIASING CYTOKINES IL-12 AND IFN-ALPHA", The Journal of immunology, 160(3), 1998, pp. 1139-1147
26. MOSSE CA; MEADOWS L; LUCKEY CJ; KITTLESEN DJ; HUCZKO EL; SLINGLUFF CL; SHABANOWITZ J; HUNT DF; ENGELHARD VH
    THE CLASS-I ANTIGEN-PROCESSING PATHWAY FOR THE MEMBRANE-PROTEIN TYROSINASE INVOLVES TRANSLATION IN THE ENDOPLASMIC-RETICULUM AND PROCESSINGIN THE CYTOSOL
    The Journal of experimental medicine
    
    C.A. Mosse et al., "THE CLASS-I ANTIGEN-PROCESSING PATHWAY FOR THE MEMBRANE-PROTEIN TYROSINASE INVOLVES TRANSLATION IN THE ENDOPLASMIC-RETICULUM AND PROCESSINGIN THE CYTOSOL", The Journal of experimental medicine, 187(1), 1998, pp. 37-48
27. HOGAN KT; EISINGER DP; CUPP SB; LEKSTROM KJ; DEACON DD; SHABANOWITZ J; HUNT DF; ENGELHARD VH; SLINGLUFF CL; ROSS MM
    THE PEPTIDE RECOGNIZED BY HLA-A68.2-RESTRICTED, SQUAMOUS-CELL CARCINOMA OF THE LUNG-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IS DERIVED FROM A MUTATED ELONGATION-FACTOR-2 GENE
    Cancer research
    
    K.T. Hogan et al., "THE PEPTIDE RECOGNIZED BY HLA-A68.2-RESTRICTED, SQUAMOUS-CELL CARCINOMA OF THE LUNG-SPECIFIC CYTOTOXIC T-LYMPHOCYTES IS DERIVED FROM A MUTATED ELONGATION-FACTOR-2 GENE", Cancer research, 58(22), 1998, pp. 5144-5150
28. MOORE MM; NGUYEN D; SLINGLUFF CL; HANKS J; SPOTNITZ WD
    FIBRIN SEALANT REDUCES SEROUS DRAINAGE AND ALLOWS FOR EARLIER DRAIN REMOVAL AFTER AXILLARY DISSECTION FOR EARLY-STAGE BREAST-CARCINOMA - A RANDOMIZED, PROSPECTIVE TRIAL
    Thrombosis and haemostasis
    
    M.M. Moore et al., "FIBRIN SEALANT REDUCES SEROUS DRAINAGE AND ALLOWS FOR EARLIER DRAIN REMOVAL AFTER AXILLARY DISSECTION FOR EARLY-STAGE BREAST-CARCINOMA - A RANDOMIZED, PROSPECTIVE TRIAL", Thrombosis and haemostasis, 1997, pp. 717-717
29. MOORE MM; HARGETT CW; HANKS JB; FAJARDO LL; HARVEY JA; FRIERSON HF; SLINGLUFF CL
    ASSOCIATION OF BREAST-CANCER WITH THE FINDING OF ATYPICAL DUCTAL HYPERPLASIA AT CORE BREAST BIOPSY
    Annals of surgery
    
    M.M. Moore et al., "ASSOCIATION OF BREAST-CANCER WITH THE FINDING OF ATYPICAL DUCTAL HYPERPLASIA AT CORE BREAST BIOPSY", Annals of surgery, 225(6), 1997, pp. 726-731
30. SLINGLUFF CL
    TUMOR-ANTIGENS AND TUMOR VACCINES - PEPTIDES AS IMMUNOGENS
    Seminars in surgical oncology
    
    C.L. Slingluff, "TUMOR-ANTIGENS AND TUMOR VACCINES - PEPTIDES AS IMMUNOGENS", Seminars in surgical oncology, 12(6), 1996, pp. 446-453
31. MOSSE CA; KITTLESEN DJ; SKIPPER JCA; HENDRICKSON R; HUNT DF; SLINGLUFF CL; ENGELHARD VH
    A TYROSINASE EPITOPE IS PROCESSED AFTER TRANSLATION INTO THE ENDOPLASMIC-RETICULUM
    The FASEB journal
    
    C.A. Mosse et al., "A TYROSINASE EPITOPE IS PROCESSED AFTER TRANSLATION INTO THE ENDOPLASMIC-RETICULUM", The FASEB journal, 10(6), 1996, pp. 2523-2523
32. SKIPPER JCA; KITTLESEN DJ; HENDRICKSON RC; DEACON DD; HARTHUN NL; WAGNER SN; HUNT DF; ENGELHARD VH; SLINGLUFF CL
    SHAVED EPITOPES FOR HLA-A3-RESTRICTED MELANOMA-REACTIVE HUMAN CTL INCLUDE A NATURALLY PROCESSED EPITOPE FROM PMEL-17 GP100/
    The Journal of immunology
    
    J.C.A. Skipper et al., "SHAVED EPITOPES FOR HLA-A3-RESTRICTED MELANOMA-REACTIVE HUMAN CTL INCLUDE A NATURALLY PROCESSED EPITOPE FROM PMEL-17 GP100/", The Journal of immunology, 157(11), 1996, pp. 5027-5033
33. SKIPPER JCA; HENDRICKSON RC; GULDEN PH; BRICHARD V; VANPEL A; CHEN Y; SHABANOWITZ J; WOLFEL T; SLINGLUFF CL; BOON T; HUNT DF; ENGELHARD VH
    AN HLA-A2-RESTRICTED TYROSINASE ANTIGEN ON MELANOMA-CELLS RESULTS FROM POSTTRANSLATIONAL MODIFICATION AND SUGGESTS A NOVEL PATHWAY FOR PROCESSING OF MEMBRANE-PROTEINS
    The Journal of experimental medicine
    
    J.C.A. Skipper et al., "AN HLA-A2-RESTRICTED TYROSINASE ANTIGEN ON MELANOMA-CELLS RESULTS FROM POSTTRANSLATIONAL MODIFICATION AND SUGGESTS A NOVEL PATHWAY FOR PROCESSING OF MEMBRANE-PROTEINS", The Journal of experimental medicine, 183(2), 1996, pp. 527-534
34. SLINGLUFF CL
    UNTITLED
    Annals of surgery
    
    C.L. Slingluff, "UNTITLED", Annals of surgery, 221(4), 1995, pp. 435-436
35. SLINGLUFF CL; HUNT DF; ENGELHARD VH
    DIRECT ANALYSIS OF TUMOR-ASSOCIATED PEPTIDE ANTIGENS
    Current opinion in immunology
    
    C.L. Slingluff et al., "DIRECT ANALYSIS OF TUMOR-ASSOCIATED PEPTIDE ANTIGENS", Current opinion in immunology, 6(5), 1994, pp. 733-740
36. COX AL; SKIPPER J; CHEN Y; HENDERSON RA; DARROW TL; SHABANOWITZ J; ENGELHARD VH; HUNT DF; SLINGLUFF CL
    IDENTIFICATION OF A PEPTIDE RECOGNIZED BY 5 MELANOMA-SPECIFIC HUMAN CYTOTOXIC T-CELL LINES
    Science
    
    A.L. Cox et al., "IDENTIFICATION OF A PEPTIDE RECOGNIZED BY 5 MELANOMA-SPECIFIC HUMAN CYTOTOXIC T-CELL LINES", Science, 264(5159), 1994, pp. 716-719
37. SLINGLUFF CL; COX AL; STOVER JM; MOORE MM; HUNT DF; ENGELHARD VH
    CYTOTOXIC T-LYMPHOCYTE RESPONSE TO AUTOLOGOUS HUMAN SQUAMOUS-CELL CANCER OF THE LUNG - EPITOPE RECONSTITUTION WITH PEPTIDES EXTRACTED FROM HLA-AW68
    Cancer research
    
    C.L. Slingluff et al., "CYTOTOXIC T-LYMPHOCYTE RESPONSE TO AUTOLOGOUS HUMAN SQUAMOUS-CELL CANCER OF THE LUNG - EPITOPE RECONSTITUTION WITH PEPTIDES EXTRACTED FROM HLA-AW68", Cancer research, 54(10), 1994, pp. 2731-2737
38. SLINGLUFF CL; STIDHAM KR; RICCI WM; STANLEY WE; SEIGLER HF
    SURGICAL-MANAGEMENT OF REGIONAL LYMPH-NODES IN PATIENTS WITH MELANOMA- EXPERIENCE WITH 4682 PATIENTS
    Annals of surgery
    
    C.L. Slingluff et al., "SURGICAL-MANAGEMENT OF REGIONAL LYMPH-NODES IN PATIENTS WITH MELANOMA- EXPERIENCE WITH 4682 PATIENTS", Annals of surgery, 219(2), 1994, pp. 120-130
39. SLINGLUFF CL; REINTGEN D
    MALIGNANT-MELANOMA AND THE PROGNOSTIC IMPLICATIONS OF PREGNANCY, ORAL-CONTRACEPTIVES, AND EXOGENOUS HORMONES
    Seminars in surgical oncology
    
    C.L. Slingluff e D. Reintgen, "MALIGNANT-MELANOMA AND THE PROGNOSTIC IMPLICATIONS OF PREGNANCY, ORAL-CONTRACEPTIVES, AND EXOGENOUS HORMONES", Seminars in surgical oncology, 9(3), 1993, pp. 228-231